REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Adult > Chapters > 3. Respiratory System >

BNSSG Adult Joint Formulary

3.5 Interstitial Lung Disease

Last edited: 19-06-2024

First line drugs Second line drugs Specialist drugs Secondary care drugs

Antifibrotics

Pirfenidone (TLS Red)

Commissioned by NHS England Specialised Services Commissioning via Prior Approval Scheme on Blueteq

  • NICE TA504 Pirfenidone - treatment of idiopathic pulmonary fibrosis

Nintedanib (TLS Red)

Commissioned by NHS England Specialised Services Commissioning via Prior Approval Scheme on Blueteq

  • NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis
  • NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
  • NICE TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

 

Disease Modifying Anti-Rheumatic Drugs (DMARDs)

Azathioprine (TLS Amber 1 month) (SCP Click here

Methotrexate (TLS Amber 1 month) (SCP Click here)

  • When used for sarcoidosis

Mycophenolate (TLS Amber 3 months) (SCP Click here

  • When used for immunomodulation / immunosuppression (unlicensed) under specialist supervision

 

Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.